Bortezomib (PS-341)

目录号:S1013 别名: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。

规格 价格 库存 购买数量  
RMB 571.94 现货
RMB 2188.92 现货
RMB 5488.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献145篇:

客户使用该产品的22个实验数据:

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。
靶点
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外研究

Bortezomib,一种硼酸二肽,是一种26S蛋白酶体的高选择性可逆抑制剂,其作用于错误折叠蛋白的降解,并且对细胞周期的调控是必要的。暴露于Bortezomib能够稳定p21,p27,和p53,以及促凋亡Bid和Bax蛋白,微囊蛋白-1,和抑制剂κB-α,这防止了核因子κB诱导的细胞存活途径的激活。Bortezomib也会促进促凋亡c-Jun-NH2末端激酶,以及内质网应激反应的激活。这些细胞蛋白水平的改变导致对增殖,迁移的抑制,和癌细胞凋亡的促进。[2] Bortezomib能够渗透到细胞,并抑制蛋白酶体介导的细胞内长寿蛋白水解,抑制50%蛋白质水解的浓度为∼0.1 μM。Bortezomib对衍生自美国国家癌症研究所(NCI)多重人类肿瘤的一组60个癌细胞系的IC50值为7 nM。PC-3细胞用Bortezomib (100 nM)处理8小时导致细胞积聚在G2-M期,相应的G1期细胞数量减少。Bortezomib在24和48小时杀死PC-3细胞,IC50分别为100和20 nM。Bortezomib治疗16-24小时后诱导细胞核缩合。Bortezomib在低至100 nM浓度下以时间依赖的方式导致PARP裂解,在处理24小时后产生效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NWm0R2VlS3m2b4TvfIlkKEG|c3H5 NXnjeHdnPTBizszN NXmyfYZ3PDhiaB?= MVzEUXNQ MmrMT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> M2fXc|ExPDl7NkSz
OVCA 429 NYX5cI56TnWwY4Tpc44hSXO|YYm= NFLzN2Q{ODBibl2= NIDMRZc1QCCq NET3SmlFVVOR MYPEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= MUOxNFk6QTd4Nh?=
RPMI8226 NIrxS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\TS|ExOCCwTR?= MkPZOFghcA>? NF3oN|BFVVOR NX\EXXdNUUN3ME2zNEBvVQ>? NVvLTIRLOTF|ME[0PFk>
Dox40 NH7lXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP2NWQyODBibl2= MoPhOFghcA>? MVzEUXNQ NVfCVJY6UUN3ME20NEBvVQ>? M4PqVlEyOzB4NEi5
MR20 NGXGNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNFAhdk1? M{PoWlQ5KGh? M3uwdmROW09? MmfsTWM2OD1{MDDuUS=> NWroOVR2OTF|ME[0PFk>
LR5 NGjVXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle1NVAxKG6P MmPrOFghcA>? NFizZ|VFVVOR MY\JR|UxRTJyIH7N MlflNVE{ODZ2OEm=
U266 MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmxNFAhdk1? MUC0PEBp NEHpbZFFVVOR MnzUTWM2OD1|IH7N NWLIO4M1OTF|ME[0PFk>
IM-9 NXnWZolDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnifFhKOTByIH7N MVi0PEBp MXTEUXNQ MnPWTWM2OD14IH7N NHLQV2gyOTNyNkS4PS=>
Hs Sultan NFv6O4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGroVlAyODBibl2= NGjmRm01QCCq NUHxXW5ETE2VTx?= MWDJR|UxRTJyIH7N M2\HeVEyOzB4NEi5
PAM-LY2 MX3GeY5kfGmxbjDBd5NigQ>? M4jSb|ExOCCwTR?= M3uxclEzKGh? MVHEUXNQ M4TD[2lvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u NHToTFAyOTN3MEmxNy=>
PAM 212 NIXnTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxNFAhdk1? NVLaZYplPzJiaB?= M1LWOWROW09? M4mw[mlvcGmkaYTzJINmdGxidnnhZoltcXS7 MoLtNVE{PTB7MUO=
PAM-LY2 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITES4EyODBibl2= NVHR[|BzPzJiaB?= MV3EUXNQ MYXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M3SyNFEyOzVyOUGz
B4B8 NFTHd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNFAhdk1? NX\zXnh1PzJiaB?= M4n3UGROW09? M4jiR2lvcGmkaYTzJINmdGxidnnhZoltcXS7 MmrNNVE{PTB7MUO=
B7E3 NHnEdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\YRlExOCCwTR?= NFjyTm84OiCq MY\EUXNQ NX30cml{UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MnXtNVE{PTB7MUO=
UM-SCC-9 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDs[lI1OTByIH7N NVzpO3c4PzJiaB?= NHq4bVRFVVOR NXLURXlXUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M{TaSlEyOzVyOUGz
UM-SCC-11B MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XaSlExOCCwTR?= NXnkcIZZPzJiaB?= MY\EUXNQ MlfUTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MVSxNVM2ODlzMx?=
H460 M2\pemZ2dmO2aX;uJGF{e2G7 MlHHNVAh|ryP MWOyOEBp NIPz[|RFVVOR M2HJTmlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? NH7vUmYyOjR7MkGxOy=>
U266 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XWZlUxOCCwZz;tcC=> NVnEb2NiPDhiaB?= MWDEUXNQ MUnJcohq[mm2czDj[YxtKGe{b4f0bC=> NFHKSIUyOjZ|MU[xPS=>
ARH77 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW1NFAhdmdxbXy= MYG0PEBp MUTEUXNQ MnLDTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MnnMNVI3OzF4MUm=
WAD-1 NUPjcWJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC0NGppPTByIH7nM41t MoHFOFghcA>? NEHTWXNFVVOR MVnJcohq[mm2czDj[YxtKGe{b4f0bC=> Mn7YNVI3OzF4MUm=
U266/LR7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnib4VnPTByIH7nM41t M1GzXFQ5KGh? MlT6SG1UVw>? M4G5W2lvcGmkaYTzJINmdGxiZ4Lve5Rp NYLnZYs4OTJ4M{G2NVk>
U266/dox4 NV\tZYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PCZlUxOCCwZz;tcC=> M1m4RlQ5KGh? MXLEUXNQ M2r0fWlvcGmkaYTzJINmdGxiZ4Lve5Rp M{fXNVEzPjNzNkG5
RPMI8226/LR5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm0W3BtPTByIH7nM41t MorzOFghcA>? NULNbItZTE2VTx?= NHHCOlFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MWWxNlY{OTZzOR?=
H460 M2nZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTQNVAh|ryP MnnNO|IhcA>? M3XyVWROW09? NHPSeGhKSzVyPUGwNEBvVQ>? M2HMN|EzPjNzNkKw
H358 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xNEDPxE1? M1X5elczKGh? NGLRbohFVVOR MVrJR|UxRTdyIH7N MVixNlY{OTZ{MB?=
H322 M1jpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D1UFExKM7:TR?= NVz5e3h2PzJiaB?= NFf1PXZFVVOR M1mxd2lEPTB;NkKwJI5O NXLiTFdGOTJ4M{G2NlA>
H460 M4rlVWZ2dmO2aX;uJGF{e2G7 MXmxNFAhdk1? MV[yOEBp NUH2enVJTE2VTx?= M{fDSGlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? NUe0eGhxOTJ4M{G2NlA>
LNCap-Pro5 MkP1SpVv[3Srb36gRZN{[Xl? MYixJO69VQ>? NVjNWJA5PCCq NUXBU2V1TE2VTx?= NVPUWYloW3SjYnnsbZpmeyCyNUO= MofrNVQ3OTJ3M{K=
T29 M1XSXWFxd3C2b4Ppd{BCe3OjeR?= NF\HU2M2OCCwTR?= M3;1O|Q5KGhi M2T6W2ROW09? M{flZ2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MU[xOlc4QDF5OR?=
T29Kt1 NGXzWINCeG:ydH;zbZMhSXO|YYm= NYe4Smc4PTBibl2= NH;CTGk1QCCqIB?= M4P4RWROW09? NHXN[|NKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYrweWxJOTZ5N{ixO|k>
HCT116 M2q5U2Fxd3C2b4Ppd{BCe3OjeR?= MYm1NEBvVQ>? M2f3WVQ5KGhi MVzEUXNQ MUjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVWxOlc4QDF5OR?=
HKe-3 MXLBdI9xfG:|aYOgRZN{[Xl? Mk\DOVAhdk1? MXu0PEBpKA>? MmrVSG1UVw>? NECyc3JKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVryNpBoOTZ5N{ixO|k>
NB-1691 MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTTfWp[OSEQvF2= M3HPTlczKGh? NWfBdGdoUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEWl MmfONVc3QDl4OES=
CHLA-255 M3\ZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiNUDPxE1? M{XFR|czKGh? NFvGWXJKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NUPGeIxyOTd4OEm2PFQ>
SK-N-AS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fZdFEh|ryP M17vRVczKGh? M4HYbWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= M1nIZlE4Pjh7Nki0
NB-1691 MkLRSpVv[3Srb36gRZN{[Xl? MYOxNEBvVQ>? MnrYNlQhcA>? MV\TbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl NXjpcoN7OTd4OEm2PFQ>
CHLA-255 M3LYcGZ2dmO2aX;uJGF{e2G7 NV\YXVZbOTBibl2= MmHFNlQhcA>? M1PrRm1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn NH\iUpkyPzZ6OU[4OC=>
RPMI 8226 MYTGeY5kfGmxbjDBd5NigQ>? NXvnTWt7OjBibl2= MVO4JIg> M4LPVXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NEXGcWoyQTR|NkC1NC=>
MM.1S NHHoXlhHfW6ldHnvckBCe3OjeR?= MnTYNlAhdk1? NUXLfoJPQCCq MUTTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MYKxPVQ{PjB3MB?=
U266 MlG4SpVv[3Srb36gRZN{[Xl? MoG0NlAhdk1? NFP4SIE5KGh? MWrTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MXyxPVQ{PjB3MB?=
OPM1 NHy4OFZHfW6ldHnvckBCe3OjeR?= NILjNnEzOCCwTR?= MWK4JIg> MWnTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NXX6dldXOTl2M{[wOVA>
INA6 MoPjSpVv[3Srb36gRZN{[Xl? NUjtbYgxOjBibl2= M2fDPVghcA>? MUnTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M3T5NFE6PDN4MEWw
OPM2 NVTqNZBwTnWwY4Tpc44hSXO|YYm= MUOyNEBvVQ>? NIrM[Wo5KGh? NWPWWHNZW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NE[3Xm8yQTR|NkC1NC=>
RPMI 8226 NELDR45HfW6ldHnvckBCe3OjeR?= NFjxWI8zOCCwTR?= NVvYVYpRQCCq MXXJcoR2[2W|IFTORUB{gW62aHXzbZM> M2W0OFE6PDN4MEWw
BaF/3 MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPOfJQyODBibl2= NE\6UmQ1QCCq NGLCeVlKSzVyPU[uNkBvVQ>? NGjwcJkzODNyNU[5Ni=>
BaF/3-p210 NHOxZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\heFExOCCwTR?= NX;LNGZtPDhiaB?= MY\JR|UxRTRwNzDuUS=> MnS1NlA{ODV4OUK=
TCC-S M1vaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXXfY0yODBibl2= MoKxOFghcA>? Ml[2TWM2OD1{Lkigcm0> MmjTNlA{ODV4OUK=
BaF/3 MYnGeY5kfGmxbjDBd5NigQ>? NELMWVA3KG6P MkHxOFghcA>? MU\JcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= MkPFNlA{ODV4OUK=
BaF/3-p210 MV\GeY5kfGmxbjDBd5NigQ>? M4m0dVYhdk1? NUjRXHM2PDhiaB?= M4TOVWlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NUHoeVZHOjB|MEW2PVI>
BaF/3-p210 NVHBNmQ2TnWwY4Tpc44hSXO|YYm= NXfOdoZwPiCwTR?= MVGyOEBp NHXYPXdT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?= NGWwV|MzODNyNU[5Ni=>
Raji M{jadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rWe|Eh|ryP NIryNoUzPCCq MWTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M4LHflIyOTdyOUi4
LCL-1 NUPNdnk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLQPFlZOSEQvF2= MoDXNlQhcA>? MVfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NEjtUY0zOTF5MEm4PC=>
LCL-2 M13LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37FW|Eh|ryP M33tOlI1KGh? NGf0d5lT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NWXkW4l[OjFzN{C5PFg>
BJAB M3vWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTzTo93OSEQvF2= M1jq[|I1KGh? NUCxdVRkWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MXSyNVE4ODl6OB?=
SNT-13 NVX2cVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxJO69VQ>? NVPh[I5ROjRiaB?= NYHrR5FnWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MYeyNVE4ODl6OB?=
SNT-16 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\yVVEh|ryP NIDOWoQzPCCq MmnlVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MU[yNVE4ODl6OB?=
Jurkat NIfHWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fyfVEh|ryP NVewOnY4OjRiaB?= NXfXcJFEWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MV2yNVE4ODl6OB?=
KAI-3 NFjMXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxJO69VQ>? MYSyOEBp M3K3W3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M3j4TlIyOTdyOUi4
SNK-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjQNUDPxE1? M2K3PFI1KGh? NHvzOZFT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MU[yNVE4ODl6OB?=
KHYG-1 NUO2RolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Sye|Eh|ryP NIrRVoczPCCq NVi4XIt3WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M2PoXlIyOTdyOUi4
SNT-16 M3r3U2Fxd3C2b4Ppd{BCe3OjeR?= M{jhN|Eh|ryP NGDF[lU3KGh? NILQTHRKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlfMNlEyPzB7OEi=
Jurkat M{\ndGFxd3C2b4Ppd{BCe3OjeR?= Mle5NUDPxE1? NYixT4E3PiCq MXTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUDM[Wp7OjFzN{C5PFg>
KAI-3 MWXBdI9xfG:|aYOgRZN{[Xl? MYCxJO69VQ>? NVfEb|VbPiCq MXHJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2H4PVIyOTdyOUi4
KHYG-1 M37wUWFxd3C2b4Ppd{BCe3OjeR?= M{nWcFEh|ryP MlrYOkBp M331[Wlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3z3PVIyOTdyOUi4
SNT-13 NIOzTlhCdnSrdnnyZYwhSXO|YYm= M1vXWFEh|ryP NWHD[FR6OjRiaB?= NVL0cZpPUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY NEDEOGczOTF5MEm4PC=>
SNT-16 NXu5SmZOSW62aY\pdoFtKEG|c3H5 NXPUcnZFOSEQvF2= MWSyOEBp NFXYSXpKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MkDXNlEyPzB7OEi=
KAI-3 MmjTRY51cX[rcnHsJGF{e2G7 MorkNUDPxE1? NH25TVMzPCCq MmG0TY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MlLPNlEyPzB7OEi=
SNK-6 MVTBcpRqfmm{YXygRZN{[Xl? NH3yTY8yKM7:TR?= M2e2[VI1KGh? M4Xsbmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MXOyNVE4ODl6OB?=
RAW 264.7 NInvWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LmdVExOCCwTR?= NFPuVnA1QCCq M{n1NnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NY\ue3lIOjJ2MkexOVQ>
A375 M4jWcWFxd3C2b4Ppd{BCe3OjeR?= NFLjWoUyOCCwTR?= M2LVTlI1KGh? MWXJcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mn7lNlMxPzlyOEO=
BLM M3nle2Fxd3C2b4Ppd{BCe3OjeR?= NF[yd2IyOCCwTR?= MoX1NlQhcA>? NX\xTo9HUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3XleFI{ODd7MEiz
A375 NXTrUmYySXW2b4DoZYd6KEG|c3H5 NVztXo1oOTBibl2= M{TwdFEzKGh? M4fVfmlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MoDZNlMxPzlyOEO=
BLM M1qyR2F2fG:yaHHnfUBCe3OjeR?= M4DhR|ExKG6P NIPQWZYyOiCq M2jWRWlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz M2SyeVI{ODd7MEiz
H1299 NEnOTY9CeG:ydH;zbZMhSXO|YYm= MmTMPFAhdk1? NHLZXGIzPCCq Ml\aSG1UVw>? MnryV4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN? NGjpV|UzPTN{M{[5Ny=>
Hut-78 NFHlR2ZHfW6ldHnvckBCe3OjeR?= M{DxXFExOCCwTR?= MWSyOEBp M{CxWGROW09? MlHhSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MYWyOVY5OTN|NR?=
H9 M1rpUmZ2dmO2aX;uJGF{e2G7 NYPVPHZKOTByIH7N MXKyOEBp M2DBdGROW09? NV;WcW1JTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u NGX4fHIzPTZ6MUOzOS=>
HH NHHsPFNHfW6ldHnvckBCe3OjeR?= M3j6ZlExOCCwTR?= NHHFbYUzPCCq NELQWnlFVVOR NYX6VllS\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u NVzRSnNOOjV4OEGzN|U>
Hut-78 MoPXUYloemG2aX;uJGF{e2G7 MWexNFAhdk1? MoXyNlQhcA>? MYHEUXNQ MV7S[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn NXfkZ2xwOjV4OEGzN|U>
HH NXy5SJVzVWmpcnH0bY9vKEG|c3H5 M3vrPFExOCCwTR?= Mn3iNlQhcA>? MlzESG1UVw>? NYTBZnFOWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> MlPUNlU3QDF|M{W=
U937 M{nnemZ2dmO2aX;uJGF{e2G7 MlvkNVAxKG6P M{jMUFYhcA>? MYXJcoR2[2W|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{ NX\BWGdQOjV5OUG0O|c>
human PBMC NEewe3BHfW6ldHnvckBCe3OjeR?= MWKxNFAhdk1? MkLFNlQhcA>? NFfy[YpKdmS3Y3XzJGlNNThicnXs[YF{\Q>? MX[yOVc6OTR5Nx?=
ES6 NVW5b|IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT4XJpSUUN3ME2wMlAxOjFibl2= MXHTRW5ITVJ?
SK-UT-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\UToRrUUN3ME2wMlE3OyCwTR?= NF\0cnVUSU6JRWK=
SH-4 NH74d4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;5dWlEPTB;MD6xO|Mhdk1? NYXOfYltW0GQR1XS
TE-9 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHWO2RZUUN3ME2wMlE5OiCwTR?= M2GyUHNCVkeHUh?=
A253 M1HJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPJNVV[UUN3ME2wMlIxQCCwTR?= M330b3NCVkeHUh?=
no-10 NVXzbmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPuTWM2OD1yLkKxJI5O NXzqWXFsW0GQR1XS
MMAC-SF NUXiVJhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMkG2JI5O MUDTRW5ITVJ?
A101D NXXZXm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLFTWM2OD1yLkKyOUBvVQ>? NEC0[phUSU6JRWK=
NTERA-S-cl-D1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSwTWM2OD1yLkK0N{BvVQ>? MVnTRW5ITVJ?
8-MG-BA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMkWgcm0> NWCyV41QW0GQR1XS
KNS-42 NHrPbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PXVWlEPTB;MD6yOVghdk1? M{SzcXNCVkeHUh?=
LXF-289 NWDKN3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILvR5pKSzVyPUCuNlY6KG6P MljvV2FPT0WU
OVCAR-4 NYfndnJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXyOGVKSzVyPUCuNlg6KG6P MlLrV2FPT0WU
LOUCY M2qwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fscmlEPTB;MD6yPVMhdk1? Mk\rV2FPT0WU
BB65-RCC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfwN3d7UUN3ME2wMlMxPCCwTR?= NGPQRZpUSU6JRWK=
D-542MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwM{K5JI5O NWjMfYZbW0GQR1XS
ONS-76 M1HFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi1NGRKSzVyPUCuN|Mhdk1? M{LkS3NCVkeHUh?=
BB30-HNC NXHCT4w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHCSI01UUN3ME2wMlM{PSCwTR?= MoP0V2FPT0WU
KS-1 M{DXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjxW|NKSzVyPUCuN|Qhdk1? M3TsS3NCVkeHUh?=
A388 M4W0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rSTmlEPTB;MD6zOVYhdk1? MW\TRW5ITVJ?
ES8 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInjOZFKSzVyPUCuOEBvVQ>? M4LnOXNCVkeHUh?=
MZ2-MEL MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWzN4dKSzVyPUCuOFA4KG6P MlvQV2FPT0WU
HCC2998 NWrZbYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfRU4tKSzVyPUCuOFEzKG6P MofaV2FPT0WU
D-247MG NWrlU25wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNEGzJI5O NF\WT2JUSU6JRWK=
ACN NXvyOI15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNEG3JI5O MX7TRW5ITVJ?
LB2518-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvlRZJpUUN3ME2wMlQzPSCwTR?= M1G3enNCVkeHUh?=
ES1 M2\JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwNEOgcm0> M2O1TXNCVkeHUh?=
HCE-T NGi3XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH0T5BIUUN3ME2wMlQ{QSCwTR?= MoPWV2FPT0WU
OS-RC-2 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPlZmVEUUN3ME2wMlQ1KG6P Mn\zV2FPT0WU
MFH-ino NUjy[HdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2npdGlEPTB;MD60OFMhdk1? NYSydHNnW0GQR1XS
OCUB-M MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7XTWM2OD1yLkS0O{BvVQ>? MUDTRW5ITVJ?
CP66-MEL M1HUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTUTWM2OD1yLkS3N{BvVQ>? M1zac3NCVkeHUh?=
LB771-HNC M4fSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNEe0JI5O M2TIR3NCVkeHUh?=
DSH1 NFXORYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjLTWM2OD1yLkS4JI5O MmTnV2FPT0WU
HUTU-80 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF31dZZKSzVyPUCuOVM{KG6P MV7TRW5ITVJ?
CESS MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\hcGFkUUN3ME2wMlU{QCCwTR?= MmTYV2FPT0WU
NCI-H747 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrFelBWUUN3ME2wMlU{QSCwTR?= NV3pWFl4W0GQR1XS
HT-144 M2jXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DNc2lEPTB;MD61O|Yhdk1? NWrnTVFMW0GQR1XS
COLO-829 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTuTWM2OD1yLk[xOEBvVQ>? MWTTRW5ITVJ?
A4-Fuk NXeyXWNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwNkKzJI5O NFfHWplUSU6JRWK=
GI-ME-N NUPpOHUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXSTWM2OD1yLk[zOEBvVQ>? NIrpZYlUSU6JRWK=
LB831-BLC MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNkSxJI5O Ml\mV2FPT0WU
HOP-62 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zBSGlEPTB;MD62OFchdk1? NFPZPJdUSU6JRWK=
BB49-HNC NI[wfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrGTWM2OD1yLk[1NkBvVQ>? MkP5V2FPT0WU
D-336MG NGLQZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNkW3JI5O MlXVV2FPT0WU
TK10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrEPGlKSzVyPUCuOlc6KG6P MmK5V2FPT0WU
Ramos-2G6-4C10 NUTaXJBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDXTWM2OD1yLk[5N{BvVQ>? NHW2d4JUSU6JRWK=
LB373-MEL-D NEjZdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M165dWlEPTB;MD63JI5O MU\TRW5ITVJ?
SF126 MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm1TWM2OD1yLkewNUBvVQ>? NF3teXRUSU6JRWK=
UACC-257 NELTbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX4XYJKSzVyPUCuO|Ehdk1? M3rRN3NCVkeHUh?=
KINGS-1 NHK2ZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\NfYVKUUN3ME2wMlczOiCwTR?= MmXJV2FPT0WU
LS-513 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH5UYhKSzVyPUCuO|M6KG6P M2TsPHNCVkeHUh?=
GI-1 NVr1PXdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\LPY9CUUN3ME2wMlc3PCCwTR?= NFS5c|ZUSU6JRWK=
ES7 NXntNYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\UemlEPTB;MD63OlYhdk1? MXPTRW5ITVJ?
LB2241-RCC NH3p[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XMUWlEPTB;MD64NFQhdk1? MorPV2FPT0WU
D-263MG NYi5U2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXKTWM2OD1yLkiwO{BvVQ>? NYL5SXN1W0GQR1XS
SW684 M4O1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17YcGlEPTB;MD64NlEhdk1? MnPZV2FPT0WU
ML-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjlNGViUUN3ME2wMlgzOSCwTR?= M2nsVXNCVkeHUh?=
SK-LMS-1 NFrTfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzES25KSzVyPUCuPFU1KG6P NXuwOVhzW0GQR1XS
TE-5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq4TWM2OD1yLki2OUBvVQ>? MoHsV2FPT0WU
QIMR-WIL NV7TPFJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XtOGlEPTB;MD64PFkhdk1? NFjWTYRUSU6JRWK=
NCI-H1355 M2DXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwOEm1JI5O M1zqV3NCVkeHUh?=
SNB75 M17UdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwOUGyJI5O Ml;5V2FPT0WU
RXF393 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zVdWlEPTB;MD65NVQhdk1? MXjTRW5ITVJ?
IST-MEL1 M1XtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwOUG3JI5O NIDpfoxUSU6JRWK=
SF268 NVjzcm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDUPZlKSzVyPUCuPVI{KG6P MVjTRW5ITVJ?
KALS-1 NH;sfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwOUK1JI5O M3;USnNCVkeHUh?=
HC-1 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW3TWM2OD1yLkm3OUBvVQ>? NV;nO2xlW0GQR1XS
SW872 NFfOeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPZR4NKSzVyPUCuPVk3KG6P NVTpTmZlW0GQR1XS
PSN1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jZ[WlEPTB;MT6wNUBvVQ>? MW\TRW5ITVJ?
TE-1 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwMEOgcm0> MVzTRW5ITVJ?
TE-10 NFnBSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH1WoVKSzVyPUGuNFMhdk1? MYnTRW5ITVJ?
RKO NGn4fIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml32TWM2OD1zLkC2JI5O M3PoZXNCVkeHUh?=
LC-2-ad NGS1W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G0R2lEPTB;MT6wPEBvVQ>? M4HB[3NCVkeHUh?=
SK-MM-2 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXITWM2OD1zLkC5JI5O NHvJcmhUSU6JRWK=
VA-ES-BJ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwMEmgcm0> NF\xUZdUSU6JRWK=
MZ7-mel MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDyNZM4UUN3ME2xMlA6KG6P MXPTRW5ITVJ?
D-392MG NUnGenJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u3NWlEPTB;MT6xJI5O NUS2NmFTW0GQR1XS
CCRF-CEM M4[1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Gyd2lEPTB;MT6xN{BvVQ>? NYS1XY5VW0GQR1XS
EM-2 NXO0UZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTMdIRKSzVyPUGuNVYhdk1? NUiwU3NsW0GQR1XS
HAL-01 M2Dsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnITG9KSzVyPUGuNVghdk1? NWi5bW06W0GQR1XS
TE-8 NF7jeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT6O3Z4UUN3ME2xMlE6KG6P NXT2Z4JrW0GQR1XS
NCI-H1882 NVPmfVBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMjDuUS=> Mo\WV2FPT0WU
Daudi NHvOUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTGTWM2OD1zLkKyJI5O MYHTRW5ITVJ?
BL-41 NULWeVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj3TWM2OD1zLkK1JI5O NVTDUHZNW0GQR1XS
SR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLkTWM2OD1zLkK1JI5O NYnEbWxUW0GQR1XS
KM12 M{XQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMkegcm0> MWrTRW5ITVJ?
K5 NYizVlJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPvTWM2OD1zLkK4JI5O M3v4VnNCVkeHUh?=
A3-KAW NX;N[pEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwMkigcm0> NV;sUIJIW0GQR1XS
CMK Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwMkmgcm0> MnXYV2FPT0WU
Calu-6 NEfwfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMkmgcm0> MmnjV2FPT0WU
IST-SL2 M{L6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPOTWM2OD1zLkOxJI5O NGmwNHpUSU6JRWK=
OPM-2 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTsbZBKSzVyPUGuN|Mhdk1? NWTpcYNZW0GQR1XS
DU-4475 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC0eoRKSzVyPUGuN|Yhdk1? MnPSV2FPT0WU
ECC12 NHKySHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[2cGlEPTB;MT6zO{BvVQ>? MmrRV2FPT0WU
L-540 NEXmflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDTTWM2OD1zLkO3JI5O NGnXcJdUSU6JRWK=
CAS-1 NEjBOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHwTWM2OD1zLkO3JI5O M3nDfnNCVkeHUh?=
PF-382 NXvSOXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Hzd2lEPTB;MT60O{BvVQ>? MYjTRW5ITVJ?
LS-411N M4fIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLHZVI{UUN3ME2xMlU{KG6P MWHTRW5ITVJ?
NCI-H69 NYn2UGd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETqS49KSzVyPUGuOVQhdk1? M2raWXNCVkeHUh?=
NB12 NHPNO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6zTWM2OD1zLkW2JI5O MVrTRW5ITVJ?
HEL NWPiR45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPCTWM2OD1zLk[xJI5O NF75W2FUSU6JRWK=
GCIY MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfy[WhKSzVyPUGuOlIhdk1? M{\XVXNCVkeHUh?=
EHEB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\uNGlEPTB;MT62O{BvVQ>? NUS1c4RIW0GQR1XS
TGBC1TKB NVjYR|ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPpSlQyUUN3ME2xMlcyKG6P M2nDdHNCVkeHUh?=
KURAMOCHI MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KxWmlEPTB;MT63NkBvVQ>? M{nHRXNCVkeHUh?=
U-266 M3rZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHSTWM2OD1zLke2JI5O NEnjWm9USU6JRWK=
LC4-1 NVzzelk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrNNYhLUUN3ME2xMlc6KG6P NHjCeZNUSU6JRWK=
NCI-H2126 NHzoNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwODDuUS=> M4PqN3NCVkeHUh?=
NCI-H1092 M{DUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\BUFlJUUN3ME2xMlghdk1? NYLORlBPW0GQR1XS
GB-1 NWfQdmo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXKS4xKSzVyPUGuPFEhdk1? MmC4V2FPT0WU
MV-4-11 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjQTWM2OD1zLkiyJI5O Mm[3V2FPT0WU
Becker NXnmUVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXWTWM2OD1zLkizJI5O NIjqUplUSU6JRWK=
MPP-89 M2C3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLCdZhKSzVyPUGuPFkhdk1? MlLyV2FPT0WU
BE-13 NHzu[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwOUOgcm0> NUfCVotSW0GQR1XS
697 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELlV2hKSzVyPUGuPVkhdk1? MUXTRW5ITVJ?
NKM-1 NYfVRpJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLsSnRKSzVyPUKgcm0> NWfvdWhpW0GQR1XS
NB13 NGezWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4[mlEPTB;MjDuUS=> MkDZV2FPT0WU
LS-123 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;MbG46UUN3ME2yMlAzKG6P MUDTRW5ITVJ?
NB17 M3;vcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDoR4FKSzVyPUKuNFQhdk1? M{LFVHNCVkeHUh?=
LAN-6 M1fIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XKVWlEPTB;Mj6wOUBvVQ>? NYfz[49SW0GQR1XS
EW-24 NWO4UXEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrXTWM2OD1{LkC4JI5O M3vmVHNCVkeHUh?=
NOS-1 NFfHR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[zcmlEPTB;Mj6xNUBvVQ>? NVfETHRDW0GQR1XS
BL-70 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwMUKgcm0> NYH2T3p[W0GQR1XS
GT3TKB M17yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHvTWM2OD1{LkGyJI5O MW\TRW5ITVJ?
HH NV7rSFBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXhTItKSzVyPUKuNVMhdk1? MoDqV2FPT0WU
KE-37 NWfC[3BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPZTWM2OD1{LkGzJI5O MX\TRW5ITVJ?
MOLT-4 NH:zbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HNW2lEPTB;Mj6xN{BvVQ>? Mlq5V2FPT0WU
EKVX NUXaPJlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwMUSgcm0> M1P1THNCVkeHUh?=
KGN MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176SGlEPTB;Mj6xOUBvVQ>? MXzTRW5ITVJ?
ES4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjaOWNKSzVyPUKuNVYhdk1? M1zqbXNCVkeHUh?=
SJSA-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPQXHhZUUN3ME2yMlIyKG6P NYnDO4ppW0GQR1XS
KMOE-2 M3;He2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXVdVRKSzVyPUKuNlMhdk1? MkLlV2FPT0WU
NB5 M{nkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfacodKSzVyPUKuNlchdk1? M2i3dXNCVkeHUh?=
BC-1 NHvVbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfhR|hKSzVyPUKuN|Ehdk1? NVnUeXN4W0GQR1XS
NB10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXITWM2OD1{LkOyJI5O NYi5R5JtW0GQR1XS
RPMI-8226 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzUTWM2OD1{LkO1JI5O MoLuV2FPT0WU
SCC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\kUZFLUUN3ME2yMlM4KG6P NHfQd3pUSU6JRWK=
ARH-77 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyRYRKSzVyPUKuN|ghdk1? Mlj2V2FPT0WU
NCI-H748 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfrV3RKSzVyPUKuN|khdk1? NGr3UZhUSU6JRWK=
KU812 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7HTWM2OD1{LkSyJI5O NFnPRXVUSU6JRWK=
NCI-H64 NHPz[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hw[2lEPTB;Mj60OEBvVQ>? NGfWd5NUSU6JRWK=
NB69 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoThTWM2OD1{LkS2JI5O NGfJSHNUSU6JRWK=
KNS-81-FD MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmizTWM2OD1{LkS4JI5O MUXTRW5ITVJ?
LB1047-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonXTWM2OD1{LkW3JI5O NIjXbXRUSU6JRWK=
EB-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPqXIxKSzVyPUKuOlYhdk1? M2DzNXNCVkeHUh?=
Mo-T NY\sW4NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwN{Sgcm0> MXLTRW5ITVJ?
EW-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrwTWM2OD1{Lke1JI5O NFrYOHpUSU6JRWK=
CTV-1 M3fm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\TdIxjUUN3ME2yMlghdk1? M1K0NHNCVkeHUh?=
ETK-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi3TWM2OD1{Lki0JI5O NHTXS2VUSU6JRWK=
C2BBe1 NF\zOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfDO3BoUUN3ME2yMlg6KG6P MYPTRW5ITVJ?
MOLT-16 NWTabZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHEd5RvUUN3ME2yMlg6KG6P M3;kbHNCVkeHUh?=
SW954 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\lTWM2OD1{Lkmgcm0> NGL2[IFUSU6JRWK=
HT NX7tVYZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjQXHJYUUN3ME2zMlAzKG6P Mnr0V2FPT0WU
KARPAS-299 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfZVFZKSzVyPUOuNFYhdk1? MmjjV2FPT0WU
MONO-MAC-6 M17Bdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\KTWM2OD1|LkGgcm0> MYnTRW5ITVJ?
CGTH-W-1 NXHTdGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwMTDuUS=> NU\rWG02W0GQR1XS
SK-PN-DW MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTNwMUSgcm0> NW[ycIszW0GQR1XS
CW-2 NH\LW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXQW|BEUUN3ME2zMlIyKG6P MmTRV2FPT0WU
SK-N-DZ MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkbVBCUUN3ME2zMlI3KG6P NFfkPItUSU6JRWK=
NEC8 M{DZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn1TWM2OD1|LkO1JI5O Ml7OV2FPT0WU
LB996-RCC M3rmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPmTWM2OD1|LkSgcm0> NXm5XYl{W0GQR1XS
DB NILtVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwNEGgcm0> Mn\aV2FPT0WU
TE-15 NITqfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrxOY1KSzVyPUOuOFMhdk1? M3H0enNCVkeHUh?=
COR-L88 NVfFNWo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnleHFGUUN3ME2zMlQ4KG6P NFzYb2pUSU6JRWK=
LAMA-84 NYq2bY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjUVYZKSzVyPUOuOFkhdk1? MYTTRW5ITVJ?
MEG-01 M3PJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr4e41iUUN3ME2zMlQ6KG6P M4TBTHNCVkeHUh?=
LOXIMVI MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\2ephuUUN3ME2zMlUhdk1? MXrTRW5ITVJ?
RPMI-8402 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6wdXlKSzVyPUOuOUBvVQ>? NInOOZJUSU6JRWK=
KARPAS-45 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy1SI9KSzVyPUOuOVQhdk1? NEm5XGtUSU6JRWK=
HCC1187 NFXNWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zvOGlEPTB;Mz61OEBvVQ>? M4PweHNCVkeHUh?=
MZ1-PC NYLpcJlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fvOmlEPTB;Mz61OEBvVQ>? NXz4eXNkW0GQR1XS
no-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fEOWlEPTB;Mz61OUBvVQ>? NUK4UHk6W0GQR1XS
EVSA-T M1zBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDuTWM2OD1|Lk[gcm0> NVHHR3Z3W0GQR1XS
DJM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULXd2dkUUN3ME2zMlY{KG6P M17MdHNCVkeHUh?=
COLO-684 M3e4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwNk[gcm0> Mm\DV2FPT0WU
NMC-G1 NEjNN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3XTWM2OD1|Lk[4JI5O M3H6T3NCVkeHUh?=
LC-1F NHzyepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITrZlZKSzVyPUOuO|Qhdk1? MoP2V2FPT0WU
RL95-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXpTWM2OD1|Lke5JI5O M1L4V3NCVkeHUh?=
COLO-320-HSR M32zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID3eI9KSzVyPUOuPVIhdk1? MYDTRW5ITVJ?
RCC10RGB NI\HPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXRV|VKSzVyPUOuPVMhdk1? MljDV2FPT0WU
HD-MY-Z MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfxTWM2OD1|LkmzJI5O NIr5[2JUSU6JRWK=
NCI-H2141 NVfmWpM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[1e5lKSzVyPUSuNFUhdk1? MX\TRW5ITVJ?
K-562 M2HVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLLNIZOUUN3ME20MlEzKG6P NY\6T5FxW0GQR1XS
NCI-H1648 NEfPfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTRwMUOgcm0> Mm\GV2FPT0WU
OMC-1 M3vUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj4eGIzUUN3ME20MlE5KG6P MWjTRW5ITVJ?
LB647-SCLC M1jWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV61VIJbUUN3ME20MlIzKG6P NGHCcY1USU6JRWK=
TE-12 M1LOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETjVZNKSzVyPUSuNlUhdk1? NFnjO5dUSU6JRWK=
NOMO-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H3SmlEPTB;ND6zN{BvVQ>? MV3TRW5ITVJ?
Raji M4fEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjiTWM2OD12LkS2JI5O NXPNeZIzW0GQR1XS
NALM-6 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHjU454UUN3ME20MlQ6KG6P MojWV2FPT0WU
HL-60 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PLZ2lEPTB;ND62O{BvVQ>? MlnHV2FPT0WU
IST-SL1 M3LkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK4NmpCUUN3ME20MlY5KG6P MmjFV2FPT0WU
MHH-PREB-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOxT3FLUUN3ME20Mlg3KG6P NEXK[W9USU6JRWK=
MHH-NB-11 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLBTWM2OD12LkmxJI5O NXHTd3liW0GQR1XS
JiyoyeP-2003 NID1RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojaTWM2OD13IH7N NIf2XYtUSU6JRWK=
SBC-1 NE\CeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwMEGgcm0> MYXTRW5ITVJ?
CHP-126 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWixTWhbUUN3ME21MlA3KG6P NVvWclQyW0GQR1XS
LU-139 M4nhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTVwMUOgcm0> NXfQNZJOW0GQR1XS
NCI-SNU-5 NF;rToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXVSlJKSzVyPUWuNVchdk1? MnPZV2FPT0WU
SW962 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWyTWM2OD13LkKxJI5O MmnmV2FPT0WU
EW-1 NGnabFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTVwM{Ggcm0> NV:4N4hEW0GQR1XS
NCI-H1417 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHlfVNKSzVyPUWuOVEhdk1? NVvFTldYW0GQR1XS
LU-65 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXacpFKSzVyPUWuPFQhdk1? NVXDeoVKW0GQR1XS
D-502MG MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn1TWM2OD14LkO3JI5O MnT6V2FPT0WU
BC-3 NX3XdYliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDhTYdWUUN3ME22MlYyKG6P M3vxRXNCVkeHUh?=
GDM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXkdmtKSzVyPU[uO|chdk1? NHrTXZpUSU6JRWK=
NCI-H2196 NGrYSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPaeFNyUUN3ME22Mlghdk1? M1yySXNCVkeHUh?=
NB1 M1TzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3UdFVqUUN3ME22Mlg5KG6P MoPlV2FPT0WU
NCI-H345 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr6TWM2OD15LkKgcm0> MYrTRW5ITVJ?
SU-DHL-1 NH3tN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTdwMkSgcm0> M1PFdnNCVkeHUh?=
JVM-2 M2eyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfEWGRqUUN3ME23MlI5KG6P MXHTRW5ITVJ?
LU-134-A NIPVUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjBbVE2UUN3ME23MlM6KG6P NVvWZol7W0GQR1XS
NCI-H1694 NXrnO5ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTdwNUigcm0> NGHQXYJUSU6JRWK=
NCI-SNU-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WyUWlEPTB;Nz62OUBvVQ>? MVrTRW5ITVJ?
L-363 NFm3PXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O4XmlEPTB;Nz63JI5O MWjTRW5ITVJ?
KG-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LYUGlEPTB;Nz65OEBvVQ>? NFHIcXlUSU6JRWK=
MN-60 NH7afJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP3ZWJJUUN3ME24MlE1KG6P NInB[pNUSU6JRWK=
NB6 NIDvUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRThwNEigcm0> M1L4ZnNCVkeHUh?=
MLMA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRThwOEWgcm0> MonQV2FPT0WU
ATN-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRThwOEmgcm0> M{jwSHNCVkeHUh?=
SK-NEP-1 NUD2b5VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;OUFdKSzVyPUmuNFEhdk1? NGnReXFUSU6JRWK=
DMS-114 NX3sUmlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTlwNkKgcm0> MWPTRW5ITVJ?
CTB-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILBRpZKSzVyPUmuOlchdk1? NYDyPZZyW0GQR1XS
NCI-H2081 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXaTWM2OD1zMD6wPUBvVQ>? M3HBPXNCVkeHUh?=
ES5 M{jHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFyLkO4JI5O NY\xcGg5W0GQR1XS
HCC1599 NHrDb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi1bHdKSzVyPUGxMlkyKG6P NGDnNWdUSU6JRWK=
NCI-H23 NYDuVHFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn61TWM2OD1zMj6xNkBvVQ>? NVHLb411W0GQR1XS
NCI-H1581 M3S4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF{LkK4JI5O M2TwbHNCVkeHUh?=
JVM-3 M{OySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPHTWZKSzVyPUGyMlk6KG6P M1;TfXNCVkeHUh?=
NCI-SNU-1 NIS2Vo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF|LkG5JI5O M1rWVXNCVkeHUh?=
NB7 NYfncmhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D3bWlEPTB;MUWuPVIhdk1? NFfDVW1USU6JRWK=
JAR MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF4LkGzJI5O Mlr0V2FPT0WU
TGW M1OzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPGXJBKSzVyPUG2MlQ5KG6P M3\UUXNCVkeHUh?=
U-87-MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT2O495UUN3ME2xOk44PiCwTR?= NULyUnYzW0GQR1XS
NCI-H1436 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3RVnpEUUN3ME2xO{4xOSCwTR?= NEDvZYNUSU6JRWK=
GOTO NX3kcoFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PmNGlEPTB;MUeuNFYhdk1? M3;yOnNCVkeHUh?=
COLO-800 NYTCS3ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF5Lk[0JI5O MnvQV2FPT0WU
MFM-223 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF5LkmxJI5O NVfMe3hWW0GQR1XS
EW-18 NELRcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTycY5KSzVyPUG3Mlk3KG6P MXnTRW5ITVJ?
NB14 M17X[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLE[mdKSzVyPUG3Mlk5KG6P NF:2NpRUSU6JRWK=
EB2 M1jyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XKOGlEPTB;MUiuNFghdk1? M362PHNCVkeHUh?=
EoL-1- NFKxcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLFTWM2OD1zOD6zNUBvVQ>? MXfTRW5ITVJ?
NCCIT NELkc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3OOHZjUUN3ME2xPE4{PiCwTR?= MX;TRW5ITVJ?
DG-75 NUjkUnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILlSlFKSzVyPUG4MlYyKG6P MWLTRW5ITVJ?
HCC2218 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF7LkWgcm0> M{jFR3NCVkeHUh?=
TE-6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PlZ2lEPTB;MkCuNFghdk1? M3q0U3NCVkeHUh?=
SF539 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn65TWM2OD1{MD62O{BvVQ>? MYLTRW5ITVJ?
NCI-H446 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLoS21KSzVyPUKxMlE5KG6P NWTHNVhWW0GQR1XS
IST-MES1 NIn6T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ{Lke3JI5O MULTRW5ITVJ?
NCI-H82 NGPHUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoflTWM2OD1{Mz6wNkBvVQ>? NXPmUWZ[W0GQR1XS
HCC2157 NITIenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zrbWlEPTB;MkOuNVMhdk1? NE\BblRUSU6JRWK=
EW-12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PmbWlEPTB;MkOuNVchdk1? NGTzdYpUSU6JRWK=
SIMA NF;QZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnENZVjUUN3ME2yN{4{QCCwTR?= MWHTRW5ITVJ?
DOHH-2 M4ix[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\3OpU4UUN3ME2yN{41PSCwTR?= Ml;1V2FPT0WU
IM-9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ|LkW0JI5O MkXqV2FPT0WU
EC-GI-10 NEKzeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ2LkKzJI5O Ml;sV2FPT0WU
HDLM-2 NVPzcGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP6TWM2OD1{ND61OEBvVQ>? Mm\2V2FPT0WU
LS-1034 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jOPWlEPTB;MkWuO|Uhdk1? Ml3jV2FPT0WU
REH NVi0cY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjoVGlKSzVyPUK2MlQyKG6P MYrTRW5ITVJ?
LU-165 M2\TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrU[JJqUUN3ME2yOk44OiCwTR?= NGHxb45USU6JRWK=
NH-12 M4i0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrTV4ZYUUN3ME2yO{43PyCwTR?= NEXPS|JUSU6JRWK=
WSU-NHL NELFNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3memFKSzVyPUK4MlM6KG6P MVTTRW5ITVJ?
ECC4 M1nTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf2cYVKSzVyPUK4Mlc6KG6P NVPTO2k{W0GQR1XS
OCI-AML2 NVTrdYtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJ7Lk[5JI5O Mo\JV2FPT0WU
EW-3 M{m1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm1Z41{UUN3ME2zNE42QSCwTR?= M3W4e3NCVkeHUh?=
NCI-H526 MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnaN3Z3UUN3ME2zNk42PCCwTR?= NUDHNnBOW0GQR1XS
NCI-H719 NGHM[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu1OGlKSzVyPUO0MlMyKG6P M{fpbHNCVkeHUh?=
KARPAS-422 M3jiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\GXYNbUUN3ME2zOU4xPCCwTR?= Mn7hV2FPT0WU
SK-MEL-1 M1TiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrFTWM2OD1|NT6xO{BvVQ>? M1yxTnNCVkeHUh?=
ES3 NXfQcIJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\UTWM2OD1|NT6xPUBvVQ>? NXL3[JR[W0GQR1XS
UACC-812 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHITWM2OD1|NT60OEBvVQ>? NIDVXplUSU6JRWK=
C8166 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN3Lkegcm0> M{\DW3NCVkeHUh?=
MDA-MB-134-VI MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrJXGZoUUN3ME2zOU45PyCwTR?= MXLTRW5ITVJ?
D-283MED NHzZbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLNTWM2OD1|Nz63PUBvVQ>? NVLUV2Z4W0GQR1XS
SHP-77 NUPaNoxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S4fGlEPTB;M{iuNFMhdk1? MXvTRW5ITVJ?
NCI-H2227 NFTZVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjhU25iUUN3ME20NE41QSCwTR?= NVP3ZVluW0GQR1XS
SKM-1 M{LrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTR{Lk[zJI5O NVvsXIx7W0GQR1XS
L-428 NVXoUllHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfoZ3ZJUUN3ME20N{45PiCwTR?= M4HmRXNCVkeHUh?=
RPMI-6666 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTR3Lki5JI5O NE\G[XJUSU6JRWK=
NCI-H716 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPV2lEPTB;NEiuPFEhdk1? NFXFXXJUSU6JRWK=
DMS-79 NY[1Z5JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnE[XZ7UUN3ME21NE44OSCwTR?= MlSzV2FPT0WU
RS4-11 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTVyLki4JI5O M{nQUXNCVkeHUh?=
NCI-H720 NWHCTmg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fnWGlEPTB;NUGuNVEhdk1? M4TkO3NCVkeHUh?=
MC-CAR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\1dJJ2UUN3ME21NU42OiCwTR?= MojoV2FPT0WU
TALL-1 M2LK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jWeGlEPTB;NUOuPVEhdk1? NVz1N3JIW0GQR1XS
NCI-N87 NInYSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTV2LkG4JI5O NGDDe|lUSU6JRWK=
P30-OHK NFvM[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\STWM2OD13ND62NUBvVQ>? NXj1bmJzW0GQR1XS
LP-1 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL4WXZKSzVyPU[xMlI5KG6P MXrTRW5ITVJ?
YT MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jqW2lEPTB;NkGuPEBvVQ>? MYLTRW5ITVJ?
MRK-nu-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rFPGlEPTB;NkGuPFIhdk1? NGrsXZpUSU6JRWK=
BT-474 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZ3IH7N M3zqenNCVkeHUh?=
NCI-H322M NXjhWWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DOVGlEPTB;Nk[uNVEhdk1? MULTRW5ITVJ?
NCI-H128 NXy4T5RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[0U29CUUN3ME23OE44PyCwTR?= MUfTRW5ITVJ?
KMS-12-PE MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MortTWM2OD15Nj6yOEBvVQ>? M3XWenNCVkeHUh?=
KP-N-YS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn22TWM2OD15Nj63OEBvVQ>? M3PhTXNCVkeHUh?=
ALL-PO NV3i[G86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXsXYFFUUN3ME23O{43PiCwTR?= Ml2wV2FPT0WU
EW-13 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jOZWlEPTB;N{euO|Yhdk1? M{L5TXNCVkeHUh?=
EW-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nnUWlEPTB;N{iuOVIhdk1? MXHTRW5ITVJ?
SK-N-FI NIjzdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;rTGl7UUN3ME24NE4zKG6P Ml76V2FPT0WU
CAL-148 NED1UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRThzLki0JI5O M1zhVHNCVkeHUh?=
RL NVHhNYZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PvNGlEPTB;OE[uNFkhdk1? MorXV2FPT0WU
AM-38 NF;INmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTwWoZHUUN3ME24PE4xQCCwTR?= MknvV2FPT0WU
RH-1 NGO2epdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjuTWM2OD17OT64OUBvVQ>? M3LuPXNCVkeHUh?=
NCI-H1770 M1HPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLOXphIUUN3ME2xNFIvPDlibl2= NYjo[W92W0GQR1XS
SIG-M5 NIL6bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj0XJZnUUN3ME2xNFUvODZibl2= NFz0TpJUSU6JRWK=
GR-ST NHrMR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjuPG01UUN3ME2xNVMvOzRibl2= MljrV2FPT0WU
ST486 NWLJVWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PPT2lEPTB;MUG0MlA3KG6P MkHQV2FPT0WU
NCI-H1650 M3nibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXkWJhUUUN3ME2xNVUvOjlibl2= NEPIVpNUSU6JRWK=
MHH-CALL-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFzNT63JI5O MkjTV2FPT0WU
BV-173 NX\HZ41kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzMU2xvUUN3ME2xNlIvPzFibl2= M{i0enNCVkeHUh?=
MC116 NFvMd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS2TWM2OD1zNEiuPFUhdk1? MknuV2FPT0WU
NCI-H524 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF3OT6xJI5O M1X2PHNCVkeHUh?=
SCLC-21H NIHSZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHyVVVKSzVyPUG1PU41OSCwTR?= M123VXNCVkeHUh?=
NCI-H1304 NGHafWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\XTWM2OD1zNkmuNlEhdk1? NYGwTnBFW0GQR1XS
NCI-H510A MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzHeXk4UUN3ME2xPFUvOzdibl2= NH\UfW1USU6JRWK=
NCI-H209 M4\W[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rv[GlEPTB;MUm2MlUzKG6P MXPTRW5ITVJ?
KM-H2 NELCVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KySmlEPTB;MUm3MlA2KG6P NF3CRoVUSU6JRWK=
NCI-H1395 NFjh[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXTd45KSzVyPUKxNE4yOyCwTR?= NFuwUGRUSU6JRWK=
NCI-H1155 NFHa[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ|MD6zNkBvVQ>? NXHIdW0yW0GQR1XS
COR-L279 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHqTWM2OD1{NUKuNVchdk1? Mm\MV2FPT0WU
NCI-H1299 M2PEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETweGFKSzVyPUK2NU44OSCwTR?= Mk[wV2FPT0WU
EW-22 NHq4OIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHnN2R3UUN3ME2yOlMvPzVibl2= M4LXVHNCVkeHUh?=
SK-MEL-2 NFHNZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fxZ2lEPTB;MkixMlkhdk1? NH3ZT41USU6JRWK=
KASUMI-1 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nQO2lEPTB;MkizMlA2KG6P MX3TRW5ITVJ?
NCI-H187 NUW3[mpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHrR4N5UUN3ME2yPFcvODhibl2= NFnuPJJUSU6JRWK=
NCI-H2171 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr4NJJKSzVyPUK4PE46OiCwTR?= MUXTRW5ITVJ?
LNCaP-Clone-FGC NWPoNW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfaTWM2OD1{OUWuNlYhdk1? MVzTRW5ITVJ?
NCI-H1522 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;qUGlEPTB;M{C3MlA2KG6P MVjTRW5ITVJ?
SCH M2rBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\rTWM2OD1|MkKuNlIhdk1? MofCV2FPT0WU
THP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXCdW9KSzVyPUOyNk43KG6P M4DOdXNCVkeHUh?=
SNU-C1 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjMb4xKSzVyPUO2Nk4xQSCwTR?= MXPTRW5ITVJ?
CA46 NF3hR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLUNIxkUUN3ME2zO|MvPjNibl2= NHLkfY1USU6JRWK=
NCI-H1963 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHoToxKSzVyPUO4Ok4yQSCwTR?= M3Pje3NCVkeHUh?=
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nyO2lEPTB;M{mxMlI4KG6P NXnkXGtlW0GQR1XS
TUR NHv5XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN7Nj62NUBvVQ>? MUjTRW5ITVJ?
NCI-H226 NVfMdHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRyMz6yN{BvVQ>? NWj4VXhTW0GQR1XS
COLO-668 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j0dGlEPTB;NECzMlU4KG6P M3HobXNCVkeHUh?=
CPC-N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7O[nZyUUN3ME20NFMvPzdibl2= NH\3PJZUSU6JRWK=
NCI-H889 NEi0VoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKzTWM2OD12NkGuPVIhdk1? MorqV2FPT0WU
J-RT3-T3-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO5OJFKSzVyPUWzNk42PyCwTR?= M2\BPXNCVkeHUh?=
MSTO-211H MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPETWM2OD13N{SuNlYhdk1? NHeweW5USU6JRWK=
SCC-15 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jvUmlEPTB;Nk[3MlQ4KG6P M37wWXNCVkeHUh?=
SUP-T1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq0TWM2OD14OE[uNFQhdk1? NWDYO5NKW0GQR1XS
DMS-153 NF;jWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTd2Nj64N{BvVQ>? NVz0cYxjW0GQR1XS
MS-1 M2S0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XINmlEPTB;N{W5MlQzKG6P NF30W4FUSU6JRWK=
TC-YIK NH\OVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv3V5ljUUN3ME23PFEvODFibl2= M3i2PXNCVkeHUh?=
RPMI-8866 NGXlNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFyME[uNlgh|ryP Mlz0V2FPT0WU
KY821 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PNOGlEPTB;MUCzOk4xPCEQvF2= NYOzd5Y6W0GQR1XS
P31-FUJ MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmThTWM2OD1zMUGyMlc2KM7:TR?= NWryWGFOW0GQR1XS
COLO-824 NWfkR|NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK0TWM2OD1zMk[xMlc5KM7:TR?= M{juV3NCVkeHUh?=
U-698-M MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLNT4lKSzVyPUKyOlIvOTVizszN NEjMbG5USU6JRWK=
TE-441-T Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ3MkGuO{DPxE1? Ml;1V2FPT0WU
IMR-5 NV[1WYNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDFRWtOUUN3ME2zOFA6NjZ{IN88US=> MUXTRW5ITVJ?
NCI-H1838 M2XaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRzOE[uN|Ih|ryP NULVVJIzW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 Bortezomib单一用药的抗癌作用已在多发性骨髓瘤的异种移植模型,成人白血病,肺癌,乳腺癌,前列腺癌,胰腺癌,头颈癌,和结肠癌,以及在黑色素瘤中得到证实。[2]在Lewis肺癌模型中,口服bortezomib (1.0 mg/ kg,每天),服用18天引起肿瘤生长延迟,并减少转移数量。Bortezomib单一用药, 高达5 mg/kg剂量时显著降低乳腺癌细胞的存活率。在前列腺癌小鼠异种移植模型中,Bortezomib (1.0 mg/kg,每周一次)用药4周减少60%肿瘤生长。1.0 mg/kg Bortezomib给药4周导致胰腺癌小鼠异种移植物生长减少72%或84%,并导致肿瘤细胞凋亡增加。1.0 mg/kg Bortezomib显著抑制人浆细胞瘤异种移植物生长,增加肿瘤细胞凋亡和总存活率,并减少肿瘤血管生成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

+ 展开

动力学法:

在典型的动力学试验中,2.00 mL试验缓冲液(20 mM HEPES,0.5 mM EDTA,0.035% SDS,pH 7.8) 和 Suc-Leu-Leu-Val-Tyr-AMC溶于DMSO,加入3 mL荧光比色皿中,并将比色皿放置于荧光分光光度计的夹套细胞皿座。反应温度通过循环水浴维持在37℃。反应溶液达到热平衡后(5 分钟),1 μL−10 μL储存酶溶液加入培养皿。伴随AMC 从多肽AMC底物裂解的反应进程通过440 nm (λex= 380 nm)下荧光发射的增加监测。
细胞实验:

[5]

+ 展开
  • Cell lines: 人多发性骨髓瘤细胞系U266
  • Concentrations: ~10 μM
  • Incubation Time: 2天
  • Method:

    通过测定细胞吸收 MTT染料的情况而测定 Bortezomib对 MM和 BMSC 生长的抑制情况。每孔使用10 μL 5 mg/mL MTT对培养48小时的细胞进行脉冲处理,至少处理4小时, 随后加入100 μL 含0.04 N HCl的异丙醇 。使用分光光度计在 570 nm处测定吸光值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 人浆细胞瘤异种移植物RPMI 8226
  • Formulation: 生理盐水
  • Dosages: 1mg/kg
  • Administration: i.v.,一周两次,使用4周,然后一周一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 384.24
化学式

C19H25BN4O4

CAS号 179324-69-7
稳定性 powder
别名 LDP-341, MLM341

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买Bortezomib (PS-341) | Bortezomib (PS-341)供应商 | 采购Bortezomib (PS-341) | Bortezomib (PS-341)价格 | Bortezomib (PS-341)生产 | 订购Bortezomib (PS-341) | Bortezomib (PS-341)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID